Recruiting

Thromboelastography Abnormalities

Sponsor:

University of Colorado, Denver

Code:

NCT05517811

Conditions

Liver Cancer

Esophageal Cancer

Colorectal Cancer

Lung Adenocarcinoma

Control

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Accepted

Interventions

TEG indices

Study Details

Brief summary:

The investigators hypothesize that abnormalities in thromboelastography (TEG) parameters in patients with liver, pancreas, biliary, esophageal, colorectal, and lung adenocarcinoma can serve as biomarkers for oncologic disease burden, cancer recurrence and overall survival as well as thrombotic and hemorrhagic post-operative complications. The investigators further hypothesize that there is histologic pathology correlates to pre-operative TEG abnormalities, and that it identifies patients with virulent tumor biology.

Conditions

Liver Cancer

Esophageal Cancer

Colorectal Cancer

Lung Adenocarcinoma

Control

Study ID

NCT05517811

Start date

Jun 26, 2022

Status verified date

Aug, 2026

Completion date

Jul 31, 2028

Anticipated

Primary completion date

May 31, 2028

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Accepted

Inclusion Criteria:

  • new diagnosis by the providing physician of hepatopancreaticobiliary, esophageal, colorectal, lung adenocarcinoma, or liver metastasis of any origin will be eligible for enrollment in the study
  • 18 Years and older

Exclusion Criteria:

  • Under 18 years old
  • prisoners
  • unable to provide informed consent
  • pregnant women
  • and those undergoing emergent or urgent operative intervention at the time of diagnosis

Study Design

Enrollment

200 participants

Anticipated

Interventions and Outcome Measures

Arms

Cancer

new diagnosis by the providing physician of hepatopancreaticobiliary, esophageal, colorectal or lung adenocarcinoma

Control

Patients undergoing major surgery

Interventions

TEG indices

Blood samples

Primary outcome measure

  • TEG indices of coagulation [ Time Frame: One Year ]
  • Disease burden as measured by TNM staging [ Time Frame: One year ]
  • Pre- operative thrombotic and hemorrhagic complications. [ Time Frame: One Year ]
  • Recurrence free and overall survival. [ Time Frame: One Year ]
  • Proteomic analysis of intro-operative sample tumor microenvironment [ Time Frame: One Year ]
  • Post-operative thrombotic and hemorrhagic complications [ Time Frame: One Year ]

Central Contacts and Locations

Central contacts

Tracey MacDermott, BA BS CCRC

303-724-2757tracey.macdermott@cuanschutz.edu

Ivan Rodriguez, MD

ivan.rodriguez@cuanschutz.edu

Locations

University of Colorado Denver

Recruiting

Aurora, Colorado, United States, 80045

Contacts

Tracey MacDermott, BA BS CCRC

303-724-2757tracey.macdermott@cuanschutz.edu

Ivan Rodriguez, MD

ivan.rodriguez@cuanschutz.edu

Principal Investigator:

Ana Fleisner, MD

UCHealth Highlands Ranch Hospital

Recruiting

Highlands Ranch, Colorado, United States, 80129

Contacts

Tracey MacDermott

303-724-2757tracey.macdermott@cuanschutz.edu

Principal Investigator:

Ana Gleisner, MD, PhD

More Information

Sponsor

University of Colorado, Denver

Last update posted

Aug 24, 2026

Last verified

Aug, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by University of Colorado, Denver on 2026-08-24.